CompletedPhase 3NCT02323529
Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1
Studying Tyrosinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swedish Orphan Biovitrum
- Principal Investigator
- Anders Bröijersén, MDSwedish Orphan Biovitrum
- Intervention
- Nitisinone(drug)
- Enrollment
- 18 enrolled
- Eligibility
- All sexes
- Timeline
- 2014 – 2015
Study locations (6)
- Swedish Orphan Biovitrum Investigational Site, Brussels, Belgium
- Swedish Orphan Biovitrum Investigational Site, Copenhagen, Denmark
- Swedish Orphan Biovitrum Investigational Site, Lyon, France
- Swedish Orphan Biovitrum Investigational Site, Giessen, Germany
- Swedish Orphan Biovitrum Investigational Site, Reutlingen, Germany
- Swedish Orphan Biovitrum Investigational site, Gothenburg, Sweden
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02323529 on ClinicalTrials.gov